- Home
- BIIB vs NTRS Comparison
BIIB vs NTRS Comparison
Compare BIIB & NTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- NTRS
- Stock Information
- Founded
- BIIB 1978
- NTRS 1889
- Country
- BIIB United States
- NTRS United States
- Employees
- BIIB N/A
- NTRS N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- NTRS Major Banks
- Sector
- BIIB Health Care
- NTRS Finance
- Exchange
- BIIB Nasdaq
- NTRS Nasdaq
- Market Cap
- BIIB 25.1B
- NTRS 22.3B
- IPO Year
- BIIB 1991
- NTRS N/A
- Fundamental
- Price
- BIIB $149.02
- NTRS $103.61
- Analyst Decision
- BIIB Buy
- NTRS Hold
- Analyst Count
- BIIB 26
- NTRS 13
- Target Price
- BIIB $248.00
- NTRS $104.54
- AVG Volume (30 Days)
- BIIB 1.6M
- NTRS 1.4M
- Earning Date
- BIIB 02-11-2025
- NTRS 01-23-2025
- Dividend Yield
- BIIB N/A
- NTRS 2.90%
- EPS Growth
- BIIB 10.05
- NTRS 51.89
- EPS
- BIIB 11.06
- NTRS 8.00
- Revenue
- BIIB $9,607,500,000.00
- NTRS $7,857,600,000.00
- Revenue This Year
- BIIB N/A
- NTRS N/A
- Revenue Next Year
- BIIB N/A
- NTRS $3.32
- P/E Ratio
- BIIB $13.47
- NTRS $12.95
- Revenue Growth
- BIIB N/A
- NTRS 16.78
- 52 Week Low
- BIIB $145.07
- NTRS $76.67
- 52 Week High
- BIIB $268.30
- NTRS $111.87
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- NTRS 45.34
- Support Level
- BIIB $145.07
- NTRS $99.36
- Resistance Level
- BIIB $149.92
- NTRS $102.73
- Average True Range (ATR)
- BIIB 3.81
- NTRS 2.31
- MACD
- BIIB 0.05
- NTRS -0.79
- Stochastic Oscillator
- BIIB 22.51
- NTRS 37.81
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About NTRS Northern Trust Corporation
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of Dec. 31, 2023, Northern Trust had assets under custody or administration of $15.4 trillion and assets under management of $1.4 trillion.